Please assess the completion status of the following clinical trial:

Trial Title: Use of Metformin to Reduce Cardiac Toxicity in Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Breast cancer requiring neoadjuvant or adjuvant therapy with doxorubicin~* Complete metabolic panel demonstrating adequate organ functions as defined by the following: Aspartate transaminase (AST) less than 2.5 times Upper Limit of Normal (ULN); Alanine transaminase (ALT) less than 2.5 times ULN; alkaline phosphatase less than 2.5 times ULN; serum creatinine less than 1.5 mg/dL; serum bilirubin less than ULN~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* Age greater than or equal to 21 years~Exclusion Criteria:~* Known diabetes~* History of cardiac arrhythmias or symptomatic cardiac disease~* Currently taking antiarrhythmic medications, beta-blockers, or other rate controlling cardiac medications~* Currently taking metformin and/or sulfonylureas~* Known hypersensitivity or intolerance to metformin~* Baseline ejection fraction of less than 50% measured by echocardiogram~* Known hypersensitivity to contrast used during echocardiogram~* Risk factors associated with increased risk of metformin-associated lactic acidosis (e.g. congestive heard failure, history of acidosis, habitual intake of 3 or more alcoholic beverages per day)~* Pregnant or breast feeding

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of Care (Type: ACTIVE_COMPARATOR): Patients will receive standard of care for their breast cancer with no metformin during their treatment with doxorubicin.
- Metformin + Standard of Care (Type: EXPERIMENTAL): Patients will receive metformin during their treatment with doxorubicin for their breast cancer.

Based on this trial design, predict the completion outcome and termination type (if applicable).